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Summary  Amyloidosis  is  a  severe  systemic  disease.  Cardiac  involvement  may  occur  in  the
three main  types  of  amyloidosis  (acquired  monoclonal  light-chain,  hereditary  transthyretin  and
senile amyloidosis)  and  has  a  major  impact  on  prognosis.  Imaging  the  heart  to  characterizeTransthyretin;
Cardiac  involvement;
Management
and detect  early  cardiac  involvement  is  one  of  the  major  aims  in  the  assessment  of  this  dis-
ease. Electrocardiography  and  transthoracic  echocardiography  are  important  diagnostic  and
prognostic  tools  in  patients  with  cardiac  involvement.  Cardiac  magnetic  resonance  imaging
better characterizes  myocardial  involvement,  functional  abnormalities  and  amyloid  deposition
due to  its  high  spatial  resolution.  Nuclear  imaging  has  a  role  in  the  diagnosis  of  transthyretin
Abbreviations: 2D-GLS, Two-dimensional global longitudinal strain; AL, light-chain amyloidosis; ASCT, Autologous stem cell trans-
lantation; ATTR, Hereditary transthyretin-related amyloidosis; cMRI, Cardiac magnetic resonance imaging; ECG, Electrocardiogram; LC,
ight-chain; LGE, Late gadolinium enhancement; LS, Longitudinal strain; LV, Left ventricular; LVEF, Left ventricular ejection fraction; NT-
roBNP, N-terminal prohormone of B-type natriuretic peptide; RV, Right ventricular; SSA, Systemic senile amyloidosis; TTE, Transthoracic
chocardiography; TTR, Transthyretin; 99mTc-DPD, 99mTc-3-3-diphosphono-1-2-propanodicarboxylic acid.
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amyloid  cardiomyopathy.  Cardiac  biomarkers  are  now  used  for  risk  stratiﬁcation  and  staging  of
patients with  light-chain  systemic  amyloidosis.  Different  types  of  cardiac  complications  may
occur, including  diastolic  followed  by  systolic  heart  failure,  atrial  and/or  ventricular  arrhyth-
mias, conduction  disturbances,  embolic  events  and  sometimes  sudden  death.  Senile  amyloid
and hereditary  transthyretin  amyloid  cardiomyopathy  have  better  prognoses  than  light-chain
amyloidosis.  Cardiac  treatment  of  heart  failure  is  usually  ineffective  and  is  often  poorly  tol-
erated because  of  its  hypotensive  and  bradycardiac  effects.  The  three  main  types  of  amyloid
disease,  despite  their  similar  cardiac  appearance,  have  speciﬁc  new  aetiological  treatments
that may  change  the  prognosis  of  this  disease.  Cardiologists  should  be  aware  of  this  disease  to
allow early  treatment.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  L’amylose  est  une  maladie  systémique  grave.  Les  3  principaux  types  d’amylose  avec
atteinte cardiaque  sont  l’amylose  à  chaînes  légères,  l’amylose  héréditaire  à  transthyrétine
et l’amylose  sénile  à  transthyrétine  non  mutée.  L’atteinte  cardiaque  conditionne  le  pronostic
dans ces  3  formes.  L’électrocardiogramme  et  l’échographie  cardiaque  sont  indispensables  pour
le diagnostic  et  l’évaluation  du  risque  de  ces  patients.  Les  biomarqueurs  cardiaques  sont  utilisés
depuis quelques  années  pour  la  stratiﬁcation  du  risque  en  particulier  dans  l’amylose  à  chaînes
légères. L’IRM  cardiaque  est  de  plus  en  plus  utilisée  pour  évaluer  ces  patients  mais  son  rôle
n’est pas  encore  bien  déﬁni.  L’imagerie  nucléaire  est  intéressante  chez  les  patients  avec  sus-
picion d’amylose  à  transthyrétine.  Les  complications  cardiaques  peuvent  être  principalement
hémodynamiques  (dysfonction  diastolique  puis  systolique),  ou  électriques  (arythmies  atriales
ou ventriculaires  malignes;  BAV  de  différents  degrés),  avec  risque  de  mort  subite.  Le  pronos-
tic de  l’amylose  à  transthyrétine  héréditaire  ou  sénile  est  meilleur  que  celui  des  amyloses  à
chaînes légères.  Malgré  une  certaine  similarité  dans  la  présentation  clinique  et  l’imagerie,  un
traitement  étiologique  spéciﬁque  existe  pour  chaque  type  d’amylose  systémique,  dont  il  peut
modiﬁer le  pronostic.  En  raison  de  l’atteinte  cardiaque  fréquente,  les  cardiologues  devraient
être sensibilisés  au  diagnostic  rapide  de  cette  maladie  aﬁn  qu’un  traitement  précoce  puisse
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Introduction
Amyloidosis  is  due  to  extracellular  tissue  deposition  of
insoluble  ﬁbrils  composed  of  a  variety  of  serum  proteins
(amyloid),  resulting  in  tissue  involvement.  Deposition  of
amyloid  can  be  localized  or  systemic  (in  virtually  all  organs
except  the  brain).  Clinical  manifestations  are  based  on  the
site  of  the  amyloid  deposits  and  are  related  to  the  type  of
precursor  protein  involved.
There  are  many  types  of  precursors  that  may  affect  the
heart:  light-chain  (LC)  immunoglobulin,  mutant  hereditary
transthyretin  (TTR),  wild-type  TTR,  mutant  apolipopro-
tein  AI,  amyloid  atrial  natriuretic  peptide  localized  to  the
atrium,  ﬁbrinogen  alpha  type  [1]  and  serum  amyloid  A
protein.  Secondary  amyloidosis  is  typically  a  consequence
of  chronic  inﬂammatory  conditions,  such  as  rheumatoid
arthritis  [2],  Crohn’s  disease  or  other  chronic  inﬂamma-
tory/infectious  diseases,  familial  Mediterranean  fever  or
idiopathic  amyloid  A  amyloidosis  [3].
The  organs  involved  are  typically  the  liver,  kidney,  gas-
trointestinal  tract,  nervous  tissue  and  heart.  The  presence
of  amyloid  deposits  in  the  heart  varies  with  the  type  of  amy-
loidosis:  systemic  senile  amyloidosis  (SSA)  and  some  forms  of
hereditary  TTR-related  amyloidosis  (ATTR)  affect  the  heart
almost  invariably,  whereas  cardiac  involvement  in  LC  amy-
loidosis  (AL)  is  present  in  about  50%  of  cases.  In  secondary
amyloidosis,  cardiac  involvement  is  rare  or  minimal  or  clin-
ically  non-signiﬁcant  [4].
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bs  droits  réservés.
The  present  review  focuses  on  the  three  main  types  of
ystemic  amyloidosis  (AL,  ATTR  and  SSA)  and  describes  car-
iac  involvement.
ight-chain amyloidosis
L  is  not  rare,  with  a reported  incidence  in  USA  of  8.9
er  million  person-years,  and  is  probably  underdiagnosed
5]. The  estimated  incidence  of  AL  in  France  is  roughly
00  patients  per  year.  AL  is  caused  by  the  extracellular
eposition  of  ﬁbril-forming  monoclonal  immunoglobulin  LCs,
sually  secreted  by  a  small  plasma  cell  clone.  The  ﬁbrils  con-
ist  of  monoclonal  kappa  or  lambda  LCs  [5]. A  serum  and/or
rine  monoclonal  component  is  detectable  by  immunoﬁxa-
ion  and/or  immunoelectrophoresis  in  80—90%  of  patients.
ith  the  use  of  sensitive  techniques,  such  as  nephelemetric
easurement  of  serum  free  LCs,  an  abnormal  concentra-
ion  of  serum  free  LCs  is  found  in  >  90%  of  patients,  with  an
ver-representation  of  the  lambda  isotype  compared  with
he  kappa  isotype  [6].  Plasmocytosis  is  present  in  the  bone
arrow  in  >  50%  of  patients.
The  diagnosis  of  AL  is  always  based  on  histological
ndings  using  light  microscopic  examination,  showing  amor-
hous  extracellular  Congo  red  positive  deposits  (Fig.  1A),
hich  display  characteristic  dichroism  and  apple  green
irefringence  under  polarized  light  (Fig.  1B)  Non-invasive
iopsies  of  abdominal  fat  and  minor  salivary  glands  should
530  D.  Mohty  et  al.
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aigure 1. Typical amorphous extracellular Congo red-stained pos
epositions (A), which display characteristic dichroism and apple gr
e  performed  initially;  the  latter  biopsy  is  usually  positive
n  80%  of  patients.  If  necessary,  i.e.  when  tissue  biopsies  fail
o  demonstrate  amyloid  deposition,  biopsy  of  a  clinically
ffected  organ  (kidney,  gastrointestinal  tract  or  endomy-
cardial  tissue)  should  be  considered.  Electron  microscopy
ay  be  useful  to  conﬁrm  the  presence  of  amyloid  deposits,
hich  typically  display  the  ultrastructural  appearance  of
andomly  arranged  ﬁbrils  (Fig.  2),  7—10  nm  in  external  diam-
ter.  Immunohistological  typing  is  indispensable  to  make  the
ifferential  diagnosis  between  different  types  of  amyloid
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igure 2. Typical electrocardiogram appearance of amyloidosis of the
xis and poor R-wave progression in the precordial leads.deposits under ﬂuorescent light source showing important amyloid
birefringence under polarized light (B).
isease  (AL  versus  ATTR  wild-type,  mutant  or  with  other
recursors).
iagnostic criteria for cardiac involvementardiac  involvement  is  one  of  the  most  frequent  types
f  solid  organ  manifestation  [5]. In  patients  with  cardiac
nvolvement,  the  lambda  LC  isotype  is  the  most  frequent
nd  is  observed  in  70%  of  cases.
 heart, showing a sinus rhythm, very low voltage with an abnormal
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Since  2005,  organ  involvement  in  systemic  AL  has  been
deﬁned  by  consensus  criteria  [7],  which  were  updated  at
the  2010  meeting  of  the  International  Society  of  Amyloid-
osis  in  Rome.  Cardiac  involvement  is  characterized  by  an
increase  in  mean  wall  thickness  in  end-ventricular  diastole
of  ≥  12  mm  by  echocardiography,  with  no  other  obvious  car-
diac  cause,  associated  with  an  increase  in  the  concentration
of  N-terminal  prohormone  of  B-type  natriuretic  peptide  (NT-
proBNP)  to  >  332  ng/L  (in  absence  of  renal  failure).
Cardiac biomarkers
NT-proBNP  and  cardiac  troponin  have  been  used  widely  since
2004  for  assessing  cardiac  involvement  severity  and  progno-
sis  in  AL  [8,9]  and  a  current  staging  system—the  Mayo  Clinic
staging—has  been  established,  based  on  NT-proBNP  (cut-off
value  =  332  ng/L;  BNP  =  100  ng/L)  and  cardiac  troponin  (cut-
off  value  =  0.035  g/L),  in  order  to  stratify  patients  into
three  groups:
• high  risk  (stage  III:  both  biomarkers  are  increased);
• intermediate  risk  (stage  II:  at  least  one  biomarker  is  above
the  cut-off  value);
• low  risk  (stage  I:  both  biomarkers  are  below  the  cut-off
values).
This  Mayo  Clinic  staging  is  now  used  by  the  medical  com-
munity  before  the  choice  of  therapy  is  made.
Recently,  ultrasensitive  troponin  has  emerged  as  a  more
sensitive  biomarker  of  cardiac  injury;  thus,  another  clas-
siﬁcation  has  been  proposed  by  Kristen  et  al.  [10],  using
the  same  cut-off  value  for  NT-proBNP  and  a  cut-off  value  of
50  ng/L  for  ultrasensitive  troponin.
Another  biomarker  —  midregional  proadrenomedullin,
which  is  produced  by  many  organs,  including  the  heart  —
was  tested  in  an  Italian  study  in  2011  [11], in  130  patients
with  conﬁrmed  de  novo  AL.  The  authors  found  that  a high
concentration  of  midregional  proadrenomedullin  was  asso-
ciated  with  a  higher  early  mortality  rate  of  40%  at  6  months
when  its  value  was  >  0.75  nmol/L.
Electric disturbances
Electrocardiograms  (ECGs)  are  abnormal  in  90%  of  cases  with
cardiac  involvement.  The  largest  study  that  reported  ECG
ﬁndings  consisted  of  127  patients  with  AL  and  biopsy-proven
cardiac  involvement  seen  at  the  Mayo  Clinic  [12].  The  study
conﬁrmed  that  the  two  most  common  abnormalities  were
low  voltage  QRS  complex  (deﬁned  as  all  limb  leads  <  5  mm  in
height)  and  a  pseudoinfarct  pattern  on  the  precordial  leads
(Fig.  2),  which  were  seen  in  roughly  50%  of  the  patients
included.  Right  and  left  bundle  branch  block  are  uncommon.
Other  changes  that  may  occur  include  conduction  abnor-
malities  (such  as  second  and  third  degree  atrioventricular
block),  more  frequently  atrial  ﬁbrillation  in  about  15%  of
patients  [13]  and,  rarely,  ventricular  tachycardia  in  about  5%
of  patients.  A  recent  study  [14]  that  included  a  large  number
of  patients  with  AL  with  and  without  cardiac  involvement,
reported  that  a  fragmented  QRS  (notches  and  RsR’  pattern
in  the  absence  of  QRS  prolongation)  was  signiﬁcantly  more
frequent  in  patients  with  cardiac  amyloidosis  (28.5%  vs.531
1.7%;  P  =  0.0008).  Moreover,  the  group  with  fragmented  QRS
ad  a  signiﬁcantly  higher  mortality  rate  compared  with  the
normal’  QRS  group  (P  =  0.0008).  According  to  the  authors,
ragmented  QRS  had  a prognostic  value  independent  of  QRS
uration,  QTc  interval,  NT-proBNP  serum  concentration  and
V  wall  thickness.  However,  these  ECG  ﬁndings  are  not  spe-
iﬁc  to  cardiac  amyloidosis  and  any  severe  cardiomyopathy
ith  severe  myocardial  injury  may  be  responsible  for  a  frag-
ented  ECG,  irrespective  of  its  aetiology.
Twenty-four-hour  Holter  ECG  monitoring  might  help
o  identify  asymptomatic  ventricular/supraventricular
rrhythmias  in  >  75%  of  cardiac  AL  patients.  Complex  ven-
ricular  arrhythmias  have  been  reported  to  be  prognostic
eterminants  for  survival,  but  only  couplets  correlated  with
udden  cardiac  death  and  were  independent  predictors
f  survival  [15].  A  24-hour  Holter  ECG  may  also  show
he  absence  of  heart  rate  variability  due  to  autonomic
ysfunction,  which  is  frequent  in  cardiac  amyloidosis  [16].
Regarding  endocavitary  conduction  disturbance,  a  large
tudy  [17]  that  included  patients  with  conﬁrmed  AL  found
hat  they  all  had  normal  sinus  function.  However,  the  infra-
isian  conduction  time  was  signiﬁcantly  prolonged  (79  ms)
nd  was  independently  associated  with  the  occurrence  of
udden  death;  the  authors  concluded  that  HV  prolongation
ay  be  a  marker  of  signiﬁcant  inﬁltration  of  myocardium
y  amyloid  ﬁbrils,  which  may  be  responsible  not  only  for
entricular  tachycardia,  but  also  for  severe  atrioventricular
onduction  abnormalities  with  high  degree  atrioventricular
lock  or  asystole.
chocardiographical ﬁndings
ardiac  involvement  is  usually  characterized  by  the  pres-
nce  of  an  inﬁltrative/restrictive  cardiomyopathy  with
lassical  echocardiographical  ﬁndings,  which  have  been  well
escribed  [18,19], but  also  by  new  echocardiographical  ﬁnd-
ngs  identiﬁed  using  strain  imaging.
Transthoracic  echocardiography  (TTE)  (Fig.  3A)  typically
hows  the  following  features:
increased  LV  wall  thickness  ≥  12  mm  with  ‘brilliant’  speck-
led  appearance  of  the  myocardium  (amyloid  ﬁbrils
deposits  are  more  echogenic  than  normal  myocardium);  a
mean  LV  wall  thickness  >  15  mm  was  independently  asso-
ciated  with  worse  outcome  [20];
normal  or  small  LV  cavity;
preserved  LV  ejection  fraction  (LVEF)  >  50%  (at  least  in  the
early  stage  of  the  disease),  but  reduced  S and  E’  waves  at
the  basal,  septal  or  lateral  myocardium  level,  reﬂecting
the  poor  longitudinal  function  and  altered  LV  relaxation;
abnormal  mitral  ﬁlling  pattern,  due  to  mild  or  moderate
LV  diastolic  dysfunction  (type  I  mitral  or  pseudonor-
malized  pattern);  and  at  a  later  stage,  a  typical
severe  restrictive  mitral  ﬁlling  pattern  with  E/A  ratio  >  2,
increased  E/E’  and  small  A  wave  due  to  atrial  dysfunction;
the  elevated  LV  ﬁlling  pressure  may  lead  progres-
sively  to  left  atrial  enlargement  (diameter  >  23  mm/m2,
2 2area  >  20  cm or  maximal  volume  >  28  mL/m ),  which
seems  not  only  to  be  helpful  for  differential  diagnosis
[21],  but  also  to  be  independently  associated  with  worse
outcome  in  AL  [22];
532  D.  Mohty  et  al.
Figure 3. A. Typical echocardiography ﬁndings in cardiac amyloidosis: thickened and sparkled left ventricular (LV) walls, thickened inter-
atrial septum, mitral and tricuspid valves, thickened right ventricular free wall, small pericardial effusion, normal LV cavity size and atrial
enlargement. B. Example of a patient with light-chain amyloidosis and advanced cardiac involvement with two-dimensional altered global
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end basal longitudinal strain, despite a relative preservation of the
right  atrial  enlargement  and  dilated  vena  cave  reﬂecting
right  ventricular  (RV)  ﬁlling  pressure;
increased  interatrial  septal  thickness  (it  must  be  empha-
sized  that  this  variable  is  much  easier  to  measure
by  cardiac  magnetic  resonance  imaging  [cMRI]  than  by
echocardiography);
increased  RV  free  wall  thickness  (>  7  mm)  with  RV  systolic
and  diastolic  dysfunctions  associated  with  worse  survival
[23];
left and  right  valve  thickening,  usually  responsible  for
mild  regurgitation;
reduced  aortic  ejection  time  (<  273  ms),  described  as  a
prognostic  factor  [24];
small  pericardial  effusion  in  50%  of  cases,  the  presence
of  which  is  independently  associated  with  worse  survival
[24];  exceptionally,  an  aspect  of  large  pericardial  effusion
with  tamponade  may  reveal  the  systemic  disease  [25];
atrial  thrombi  may  be  seen,  despite  the  presence  of  sinus
rhythm;  one  large  study  that  analysed  the  presence  of
atrial  thrombi  in  patients  with  conﬁrmed  AL  [13]  found
that  AL  patients  were  younger  and  had  less  atrial  ﬁbrilla-
tion  than  those  with  other  types  of  amyloidosis;  however,
the  AL  group  had  signiﬁcantly  more  intracardiac  thrombi
(51%  vs.  16%;  P  <  0.001)  and  more  fatal  embolic  events
(26%  vs.  8%;  P  <  0.03).
iagnostic and prognostic value of new
chocardiographical techniques
 large  study  recently  published  by  Buss  et  al.  [26], which
ncluded  200  consecutive  patients  with  AL  with  systematic
ssessment  of  LV  longitudinal  function,  showed  that:  longi-
udinal  strain  (LS)  and  2D  global  LS  (2D-GLS)  were  strongly
orrelated  with  NT-proBNP  in  patients  with  AL;  reductions
n  LS  and  2D-GLS  were  both  independently  associated  with
rognosis  in  AL,  including  overall  survival,  compared  with
tandard  TTE  variables;  and  LS  and  2D-GLS  provided  incre-
ental  value  over  NT-proBNP,  cardiac  troponin  and  all  other
linical  variables  assessed.
t
r
ial longitudinal strain, named ‘the apical sparing’.
Another  recent  study  [27]  was  designed  to  show  the
iagnostic  importance  of  two-dimensional  speckle-tracking
maging  in  differentiating  cardiac  amyloidosis  from  other
auses  of  LV  hypertrophy.  Using  55  patients  with  conﬁrmed
L,  the  authors  found  that  the  amyloid  heart  is  charac-
erized  by  reduced  basal  strain  and  regional  variations  in
S  from  base  to  apex  (Fig.  3B),  and  that  a  relative  ‘api-
al  sparing’  (average  apical  LS/[average  basal  LS  +  mid-LS])
attern  of  LS  is  an  easily  recognizable,  accurate  and  repro-
ucible  means  of  differentiating  cardiac  amyloidosis  from
ther  causes  of  LV  hypertrophy.
Therefore,  this  technique  appears  useful  not  only  for
iagnosis  but  also  for  the  independent  assessment  of  prog-
osis  in  patients  with  AL.
ardiac magnetic resonance imaging
MRI  is  often  performed  when  cardiac  amyloidosis  is  sus-
ected  because  it  has  an  excellent  spatial  resolution  for
issue  characterization  and  is  very  sensitive  for  detecting
he  presence  of  inﬁltrative  cardiomyopathy,  even  in  cases
f  normal  LV  wall  thickness.
cMRI  allows  precise  measurement  of  the  LV  walls,  the
nteratrial  and  RV  free  walls,  biatrial  enlargement  and
ericardial  effusion  (Fig.  4).  cMRI  is  also  useful  for  tissue
haracterization  of  the  myocardium  [28], by  showing  dif-
erent  patterns:  transmural  late  gadolinium  enhancement
LGE)  or,  more  typically,  a large  diffuse  annular  LGE;  less
ften  a  global  heterogeneous  LGE  or  rarely  diffuse  LGE,
alled  ‘patchy  LGE’.  Indeed,  gadolinium  has  an  interstitial
istribution,  and  in  patients  with  cardiac  amyloidosis  there
s  an  increase  in  interstitial  cardiac  volume  because  normal
yocardium  is  replaced  by  amyloid  ﬁbrils.  Thus,  gadolinium
tays  longer  in  the  tissue,  which  explains  the  late  gadolinium
nhancement.The  prognostic  signiﬁcance  of  LGE  or  suboptimal  nulling
ime  (i.e.  the  determination  of  the  optimal  inversion  time
equired  to  have  the  myocardium  completely  black  in  T1)
s  not  yet  clear.  Maceira  et  al.  [29], in  a  cohort  of  29
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Figure 4. Cardiac magnetic resonance imaging. A. Short-axis section of a patient with hereditary transthyretin-related amyloidosis (ATTR)
Val122Ile mutation, showing thickening and diffuse late gadolinium enhancement (LGE) of the left ventricular wall. B. Horizontal long-axis in
an ATTR Val30Met late-onset patient, showing pericardial effusion, evidenced by diffuse LGE of the left and right ventricles, the interatrial
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patients,  suggested  that  T1  mapping  may  have  greater  abil-
ity  to  predict  outcome  than  LGE  per  se,  possibly  because  it
more  accurately  reﬂects  the  myocardial  interstitial  amyloid
load.  A  small  study  by  Mekinian  et  al.  in  2010  [30]  showed
that  the  presence  of  LGE  was  a  univariate  predictor  of  out-
come  in  patients  with  cardiac  AL;  however,  it  did  not  come
out  as  an  independent  predictor  of  survival  after  adjusting
for  the  presence  of  heart  failure  and  high  BNP  concentra-
tions.
Therefore,  the  additive  value  of  this  technique  to  existing
prognostic  indicators  requires  conﬁrmation  in  larger  series.
cMRI  may  offer  promise  for  the  early  detection  of  cardiac
involvement  using  LGE,  but  this  has  yet  to  be  proved.
Nuclear imaging
Several  single-photon  emission  computed  tomography  trac-
ers  are  used  to  visualize  myocardial  amyloid  deposits:
99mTc-aprotinin, 99mTc-Iabelled  phosphate  derivatives  and
the  serum  amyloid  P  component.  The  latter  is  labelled
with 123I,  a  glycoprotein  that  binds  in  a  calcium-dependent
manner  to  all  amyloid  deposits,  independent  of  the  pro-
tein  of  origin;  however,  this  tracer  is  useful  for  systemic
amyloidosis  but  not  for  identifying  cardiac  involvement  and
is  not  available  in  all  European  countries.  The  phosphate
derivative  single-photon  emission  computed  tomography
tracers,  labelled  with 99mTc,  have  been  used  to  detect  car-
diac  involvement  of  amyloidosis;  the  mechanism  of  uptake
seems  to  be  related  to  the  high  calcium  content  in  amyloid
deposits.  Among  these  bone  tracers, 99mTc-3-3-diphosphono-
1-2-propanodicarboxylic  acid  (99mTc-DPD)  has  been  proven  to
be  very  useful  in  the  differential  diagnosis  of  ATTR  and  AL
aetiologies.  In  AL, 99mTc-DPD  uptake  is  absent  or  weak  [31].
Although  metaiodobenzylguaninine  does  not  bind  directly
to  amyloid  deposits, 123I-metaiodobenzylguaninine  scintig-
raphy  has  been  proven  to  be  useful  for  revealing  the
impairment  of  cardiac  nerve  endings  due  to  amyloid  depo-
sition;  this  scintigraphy  seems  attractive  for  the  objective
•valuation  of  cardiac  sympathetic  level,  in  relation  to  auto-
omic  dysfunction  [32].
ardiac complications of myocardial
myloid ﬁbril deposition
ymptoms  are  non-speciﬁc:  dyspnoea  due  to  heart  failure,
yncope,  vertigo  due  to  rhythm  or  conduction  disorders
nd,  rarely,  chest  pain.  This  is  the  reason  why  diagnosis  is
elayed.  Cardiac  involvement  may  have  many  serious  con-
equences  [5,33]:
severe  congestive  heart  failure  with  initially  preserved
LVEF  and  decreased  LV  compliance  due  to  amyloid  deposit,
and  advanced  diastolic  dysfunction;
decreased  LVEF  may  follow  diastolic  dysfunction,  leading
to  terminal  and  fatal  heart  failure;
chronic  elevated  LV  ﬁlling  pressure  leads  to  left  atrial
enlargement  then  to  paroxysmal  or  persistent  atrial  ﬁbril-
lation;  atrial  thrombi  are  frequent  in  cardiac  amyloidosis,
even  in  patients  with  sinus  rhythm,  and  can  cause  sys-
temic  embolic  events;
non-sustained  or  sustained  ventricular  arrhythmias  are
also  potential  complications  of  cardiac  amyloidosis;
conduction  disturbances  are  more  frequently  encoun-
tered  in  cardiac  ATTR  and  are  prevented  and  treated  by
pacemaker  implant;
orthostatic  hypotensive  episodes  are  due  to  autonomic
dysfunction  and/or  neurovegetative  involvement  or  have
a  hypovolemic  cause;  severe  dysautonomia  can  cause
syncope  and  hypotensive  cardiac  treatment  (angiotensin-
converting  enzyme  inhibitors)  should  be  avoided  in  these
patients;
autonomic  dysfunction  can  be  also  expressed  by  the  loss
of  heart  variability;  indeed,  an  SDNN  <  50  ms  on  a  24-hour
Holter  ECG  was  found  to  be  an  independent  predictor  of
short-term  mortality  in  AL  patients  [16];
chest  pain  may  occur  in  rare  cases  where  amyloid
deposits  affect  the  microcoronary  circulation,  whereas
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the  macrocoronary  vessels  are  usually  free  of  signiﬁcant
stenosis  [34].
anagement and treatment of light-chain
myloidosis
reatment  of  AL  focuses  on  the  use  of  chemother-
py  directed  against  the  underlying  B-cell  clone-secreting
myloid-forming  immunoglobulin  LCs.
The  decrease  in  or  halting  of  the  production  of  amyloido-
enic  proteins  moves  the  balance  towards  the  elimination
f  deposits.  Therefore,  treatment  of  AL  is  equal  to  treat-
ent  of  the  underlying  plasma  cell,  lymphoplasmocytic  or
ymphoproliferative  disorder  to  rapidly  reduce  the  supply  of
he  amyloidogenic  monoclonal  LCs,  while  using  supportive
easures  to  sustain  the  function  of  the  organs  involved.
All  treatment  strategies  efﬁcient  in  multiple  myeloma  or
n  lymphoproliferative  disorders  can  be  used,  adapted  to  the
ype  of  haematological  disease  and  the  nature  and  number
f  affected  organs,  taking  into  account  their  potential  tox-
city.  The  goal  of  treatment  should  be  the  achievement  of
 haematological  response,  which  is  an  important  predictor
f  prolonged  survival.
onventional chemotherapy and intensive
reatment with stem cell transplantation
everal  studies  have  shown  the  efﬁcacy  of  high-dose
examethasone-based  regimens  in  inducing  haematologi-
al  responses  and  prolonging  survival.  Impressive  efﬁcacy,
ith  >  60%  haematological  response,  has  been  reported  with
elphalan-dexamethasone  regimens  [35],  with  median  sur-
ival  up  to  5  years.
In experienced  centres,  intensive  treatment  and  autol-
gous  stem  cell  transplantation  (ASCT)  obtains  a  similar
aematological  response  rate  [36].  However,  ASCT  remains
estricted  to  selected  patients  who  are  generally  without
dvanced  cardiac  amyloidosis.  In  2007,  a  French  multicentre
andomized  prospective  trial  showed  that,  compared  with
SCT,  melphalan-dexamethasone  had  similar  efﬁcacy  with
ess  toxicity,  resulting  in  increased  survival  (22.2  months
n  the  ASCT  group  and  56.9  months  in  the  group  with  oral
elphalan-dexamethasone;  P  =  0.04)  [35].  Whereas  ASCT
s  still  commonly  used  in  the  USA  in  patients  without
evere  disease,  it  is  no  longer  used  in  most  European
ountries,  except  Germany;  melphalan-dexamethasone  has
ecome  the  ﬁrst-line  treatment  in  France  for  the  majority
f  patients.
ovel agents
halidomide,  lenalidomide  and  the  proteasome  inhibitor
ortezomib  have  been  used  in  several  studies  with
xcellent  results  [37—39].  Bortezomib  combined  with  dexa-
ethasone  produced  clonal  response  rates  of  70—90%,
ith  40%  complete  response,  even  in  previously  treated
atients  with  refractory  disease.  The  combination  of
elphalan-dexamethasone  plus  bortezomib  was  compared
ith  melphalan-dexamethasone  in  an  international  ongoing
andomized  trial.  Bortezomib  may  also  be  combined  with
r
m
o
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yclophosphamide  and  dexamethasone  with  good  tolerance
nd  impressive  response  rates  [38,39],  and  this  combination,
ue  to  its  very  rapid  efﬁcacy,  is  now  the  treatment  of  choice
or  patients  with  Mayo  Clinic  stage  III  patients  in  France.
rognosis
n  AL,  survival  depends  mainly  on  the  extension  and  severity
f  organ  involvement,  particularly  the  presence  of  amy-
oid  heart  disease,  and  on  the  haematological  response  to
herapy.  Prognosis  is  inﬂuenced  relatively  little  by  the  under-
ying,  usually  non-proliferating,  monoclonal  plasma  cells,
ven  though  bone  marrow  plasma  cell  inﬁltration  > 10%  has
een  associated  with  poorer  outcome  [40].  Only  15  years
go,  overall  survival  in  AL  was  poor,  with  a  median  overall
urvival  of  18  months  [41].  Since  then,  the  disease  prognosis
as  been  transformed  with  the  development  of  new  strate-
ies  that  efﬁciently  suppress  secretion  of  amyloid-forming
Cs,  giving  a  median  survival  of  >  5  years.  Early  diagnosis  is
herefore  a  critical  step  to  avoid  irreversible  damage,  espe-
ially  to  the  heart.
ardiac supportive treatment
part  from  speciﬁc  treatment  of  the  underlying  haemato-
ogical  disease,  symptomatic  treatment  and  supportive  care
re  necessary  in  patients  with  organ  failure.  Most  drugs
ommonly  used  for  the  treatment  of  congestive  heart  fail-
re  are  inefﬁcient  or  appear  to  be  dangerous  in  patients
ith  AL,  ATTR  or  SSA  [42].  Beta-blockers  are  deleteri-
us  because  they  decrease  heart  rate,  which  is  the  only
echanism  that  can  maintain  cardiac  output  in  this  dis-
ase;  they  may  also  aggravate  autonomic  dysfunction  like
ngiotensin-converting  enzyme  inhibitors.  In  an  in  vitro
tudy,  digitalis  has  been  shown  to  accumulate  in  cardiac
myloid  deposits  [43];  for  this  reason,  digitalis  is  not  recom-
ended  in  patients  with  cardiac  amyloidosis.  Loop  diuretics,
iven  at  high  dosage  in  patients  with  severe  ﬂuid  retention,
re  the  mainstay  of  management.  Amiodarone  should  be
onsidered  as  ﬁrst-line  therapy  for  arrhythmia.  Anticoagula-
ion  therapy  is  mandatory  in  patients  with  supraventricular
rrhythmia  but  needs  to  be  discussed  in  patients  with  sinus
hythm  and  severe  contractile  atrial  dysfunction.  Pacemaker
mplantation  may  be  indicated  in  patients  who  develop
ymptoms  of  bradycardia  or  conduction  disorders.  A  heart
ransplant  should  be  considered  in  selected  young  patients
ith  advanced  amyloid  cardiomyopathy  [44,45],  free  from
ther  comorbidities.
ereditary transthyretin-related
myloidosis
TTR—also  named  ‘familial  amyloid  polyneuropathy’  —  was
nitially  reported  by  the  neurologist  Corino  da  Costa  Andrade
n  two  coastal  villages  of  Portugal  in  1950  [46].  Since  that
ime,  the  disease  has  been  described  as  endemic  in  Japan
1968)  and  Sweden  (1976),  and  sporadic  cases  have  been
eported  in  many  countries.  TTR  is  a  transport  protein
ainly  synthesized  by  the  liver.  The  TTR  gene  is  localized
n  chromosome  18  (18q23).  The  disease  is  transmitted  as
n  autosomal  dominant  trait  with  high  penetrance.  More
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Figure 5. Patient with cardiac hereditary transthyretin-related amyloidosis. A. Congo red staining under ﬂuorescent light source showing
important amyloid deposition. B. Positive transthyretin immunostaining.
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[than  100  pathogenic  mutations  have  been  described.  The
most  commonly  found  mutation  is  the  replacement  of  valine
by  methionine  at  position  50  (Val50Met),  ﬁrst  described  in
the  Portuguese  population.  The  variant  TTR  destabilizes  the
TTR  tetramer  and  monomers  aggregate  in  amyloid  ﬁbrils
(Fig.  5).
The  main  clinical  manifestations  are  neurological  and
cardiac.  Neurological  symptoms  (due  to  TTR  deposits)  are
sensory-motor  peripheral  neuropathy  and  autonomic  dys-
function.  The  motor  deﬁcit  involves  the  large  sensory  and
motor  nerve  ﬁbres.  Walking  becomes  increasingly  difﬁ-
cult,  with  neuropathic  pain,  leading  to  death  within  10
years  on  average  [47].  Autonomic  dysfunction  affects  the
cardiocirculatory  (orthostatic  hypotension),  gastrointestinal
and  genitourinary  systems.  Gastrointestinal  dysautonomia
aggravates  postural  hypotension  and  progressive  weight
loss.  Cardiac  manifestations  include  episodes  of  arrhyth-
mias,  syncope  or  even  sudden  death  due  to  severe
conduction  disorders,  and  dyspnoea  and  heart  failure
due  to  the  restrictive  cardiomyopathy  as  described  above
[48].
Clinical  manifestations  and  age  of  onset  vary  depending
on  the  TTR  mutation,  sex,  parental  gene  transmission  and
geographical  area  [47].  For  example,  the  Val50Met  ATTR
mutation  in  Portuguese  patients  occurs  in  their  second  or
third  decade,  with  peripheral  neuropathy  and  cardiac  con-
ductive  disorders.  In  other  geographical  areas,  the  same
Val50met  ATTR  mutation  has  a  late-onset  (at  age  50—70
years)  and  the  clinical  manifestations  combine  peripheral
neuropathy,  cardiac  conductive  disorders  and  heart  failure
[49].  In  other  ATTR  mutations  (Thr80Ala  and  Val142Ile),  car-
diac  involvement  is  predominant.
ECGs,  TTE  and  cMRI  of  cardiac  ATTR  show  similar  ﬁndings
to  cardiac  AL,  as  described  above.  In  asymptomatic  ATTR
carriers,  cMRI  may  detect  early  cardiac  involvement  by  focal
myocardial  LGE.
99mTc-DPD  scintigraphy  is  useful  for  imaging  amyloid
deposits  in  the  myocardium  of  patients  with  TTR-related
amyloidosis.  Positive  phosphate  scanning  correlates  with
high  amounts  of  amyloid  ﬁbrils  in  the  heart.  Absent  in  control
subjects, 99mTc-DPD  uptake  is  strong  in  ATTR  amyloidosis,  in
both  mutant  and  wild-type  ATTR  [31]  (Fig.  6).  The 99mTc-DPD
uptake  is  reported  to  be  a  prognostic  determinant  of  cardiac
n
i
w
Sutcome  in  ATTR,  either  alone  or  in  combination  with  LV
all  thickness  [50]. Cardiac  two-photon  excitation  imaging
ith  an  amyloid-speciﬁc  tracer  (11C-BF-227)  revealed
igniﬁcantly  robust  retention  of  tracer  in  myocardial
myloid  deposition,  promising  future  developments  [51].
The  diagnosis  strategy  for  ATTR  combines  pathology  and
olecular  genetic  testing.  ATTR  is  a  gene  of  small  size  (7  kB),
ncluding  four  exons,  and  its  screening  by  full  sequencing  of
he  coding  parts  is  now  easily  accessible.
Cardiac  medical  supportive  treatment  is  limited  and  is
imilar  to  that  for  AL.  The  speciﬁc  treatment  of  ATTR  is  a
iver  transplant  with  or  without  a  heart  transplant,  depend-
ng  on  phenotypic  presentation  and  the  age  of  the  patient.
he  liver  transplant  eliminates  the  mutated  TTR  from  the
lood,  but,  for  some  patients,  continued  amyloid  deposi-
ion  can  occur  from  wild-type  (normal)  TTR,  particularly  in
he  heart.
A  new  treatment  has  been  developed  to  stabilize  the
etramer  and  slow  down  the  progression  of  the  neuropathy
Vyndaquel®;  tafamidis)  [52]. So  far,  this  treatment  is  lim-
ted  to  patients  with  mild  or  moderate  neuropathy  and  the
ardiac  effects  of  this  drug  are  going  to  be  assessed  shortly.
ew  gene  therapies  (with  antisense  oligonucleotides  to
uppress  hepatic  TTR  synthesis)  are  also  going  to  be  tested
n  ATTR.
ystemic senile amyloidosis (also called
ild-type ATTR)
SA  is  derived  from  native  TTR,  which  results  in  the  deposi-
ion  of  TTR  mainly  in  the  heart.  The  prevalence  of  cardiac
TR  amyloid  deposits  is  estimated  at  around  10%  in  people
ged  >  80  years  and  50%  in  those  aged  >  90  years  [53].
A  study  of  85  consecutive  autopsies  in  patients  aged  >  80
ears  found  amyloid  deposits  with  positive  TTR  staining  in
5%  of  cases  [54].  SSA  affects  25%  of  the  very  aged  and  is
ssociated  with  genetic  variation  in  alpha-2-macroglobulin
55]. The  clinical  signiﬁcance  of  these  limited  deposits  is
ot  clear.  In  contrast,  in  some  rare  cases,  TTR  deposition
n  the  heart  results  in  an  important  increase  in  ventricle
alls,  mimicking  concentric  hypertrophic  cardiomyopathy.
urprisingly,  SSA  occurred  more  than  90%  in  men  (aged  >  70
536  D.  Mohty  et  al.
Figure 6. 99mTc-3-3-diphosphono-1-2-propanodicarboxylic acid (99mTc-DPD) nuclear imaging. A. Patient with cardiac systemic senile amy-
loidosis showing important 99mTc-DPD uptake in the heart. B. Cardiac 99mTc-DPD tomoscintigraphy in the same patient (the red colour
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torresponds to amyloid deposition). C. Patient with cardiac light-ch
ears).  The  mechanisms  of  normal  TTR  deposition  in  the
eart  are  unknown.
Amyloid  deposition  in  SSA  is  generally  localized  in  the
eart  and  the  carpal  tunnel.  Salivary  glandular,  rectal  or  fat
bdominal  biopsies  should  be  normal.  ATTR  gene  sequenc-
ng  is  normal  in  SSA.  SSA  is  characterized  by  an  important
ymmetric  increase  in  LV  wall  thickness  (signiﬁcantly  thicker
han  that  in  AL  and  ATTR).  History  of  myocardial  infarction,
rrhythmia  and/or  bundle  branch  block  are  present  in  one
hird  of  patients  [48].
There  is  no  speciﬁc,  consistent  sign  on  TTE  and/or  cMRI
hat  allows  the  three  main  types  of  amyloid  heart  disease  to
e  distinguished  accurately.  Endomyocardial  biopsy  is  the
nly  way  to  deﬁnitively  diagnose  SSA,  through  demonstra-
ion  of  ATTR  deposits  with  no  amyloidogenic  TTR  mutation.
owever,  endomyocardial  biopsies  are  invasive  in  elderly
atients  and  are  not  performed  for  ethical  reasons.
Nevertheless, 99mTc-DPD  scintigraphy  can  accurately
iagnose  SSA  cardiac  amyloid  deposition  (Fig.  6A  and  B),  in
ddition  to  normal  TTR  sequencing  and  normal  serum  free
C  measurement  [56].  Cardiological  treatment  is  similar  to
TTR;  however  because  patients  don’t  have  symptomatic
europathy,  as  seen  in  ATTR,  cardiac  therapeutic  agents
angiotensin-converting  enzyme  inhibitors,  beta-blockers),
enerally  already  prescribed  for  previous  myocardial
nfarction  or  hypertension,  are  better  tolerated  than  in
ther  types  of  amyloidosis.  Pacemaker  implantation  should
e  discussed,  depending  on  symptoms  and  abnormalities
n  ECGs,  24-hour  Holter  ECGs  and  electrophysiological
ndings,  if  necessary.
e
s
n
[myloidosis without heart uptake of 99mTc-DPD.
omparison between AL, SSA and ATTR
ardiac amyloidosis
t  is  not  possible  to  differentiate  AL,  ATTR  and  SSA  accurately
y  TTE  (Table  1).
A  large  longitudinal  study  [48]  that  included  233  patients
ith  a  clear-cut  diagnosis  by  type  of  amyloid  precur-
or  (AL,  n  =  157;  ATTR,  n  =  61;  SSA,  n  =  15),  compared  the
iagnostic/clinical  proﬁles  of  the  three  different  types
f  systemic  cardiac  amyloidosis.  The  main  ﬁndings  were
hat:
average  age  at  diagnosis  was  higher  in  AL  than  in  ATTR;
all  SSA  patients  except  one  were  elderly  men;
mean  LV  wall  thickness  was  higher  in  SSA  than  in  ATTR  and
AL;
LVEF  was  moderately  depressed  in  SSA  but  not  in  AL  or
ATTR;
ATTR  patients  displayed  low  QRS  voltage  less  often  (25%
vs.  60%  in  AL;  P  <  0.0001);
AL  patients  had  greater  haemodynamic  impairment.
Moreover,  by  multivariable  analysis,  AL  was  inde-
endently  associated  with  worse  survival,  whereas  SSA
redicted  freedom  from  major  cardiac  events.  The  authors
oncluded  that  AL,  ATTR  and  SSA  should  be  considered  as
hree  different  cardiac  diseases,  characterized  by  differ-
nt  pathophysiological  substrates  and  courses.  Other  studies
howed  that  cardiac  AL  was  associated  with  a worse  prog-
osis  and  more  rapid  progression  of  heart  failure  than  SSA
57]. The  difference  in  survival,  despite  evidence  of  more
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Table  1 Comparison  of  light-chain,  hereditary  transthyretin-related  and  systemic  senile  amyloidosis.
AL  Hereditary  ATTR SSA
Val30Met  early  onset Val30Met  late-onset
and  other  mutation
Val122Ile  cardiac
mutation
Clinical
Average  age  (years) 60  30  >  50 > 50 > 75
Ethnic  or  country White  and  black Portuguese French  White  and  black
(Val122Ile  prevalence
in black  population:
3—4%)
(90%  in  men)
Extracardiac
manifestations
Myeloma  or  monoclonal
gammopathies;  renal
insufﬁciency;  CTS
Neuropathy;  autonomic
dysfunction;  CTS
Neuropathy;  CTS CTS  CTS
Orthostatic  hypotension ++  ++  ++  —  —
ECG
Low  QRS  voltage  +++  —  ++  +++  ++
Pseudoinfarct  pattern +++  +  +++  +++  ++
Biomarkers
BNP,  troponin  +++  for  risk
stratiﬁcation
+ ++  +++  +++
TTE
Wall  thickness  +  ++  (usually
asymmetric)
+ +++  +++  +++  (concentric)
LVEF  Normal  or  ↓  (late)  Normal  Normal  or  ↓  (late)  Normal  or  ↓  (late)  Normal  or  ↓  (late)
LV  straina ↑↑↑  ↑  ↑↑  ↑↑↑  ↑↑↑
Restrictive  mitral  pattern  +++  —  ++  ++  ++
Other  features  RVH;  pericardial
effusion
—  RVH;  inconstant
pericardial  effusion
RVH;  inconstant
pericardial  effusion
RVH;  inconstant
pericardial  effusion
cMRI
Annular  subendocardial  ++  —  ++  ++  +
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Table  1 (Continued)
AL  Hereditary  ATTR  SSA
Val30Met  early  onset  Val30Met  late-onset
and  other  mutation
Val122Ile  cardiac
mutation
LGE  localization
Patchy  +++  +  ++  +++  +++
Nuclear  imaging
DPD  scintigraphy  +  (not  signiﬁcant)  +  +++  +++  +++
Biopsy
Positive  Congo  red  biopsy;
appropriate  staining  (TTR,
kappa,  lambda)
Immunoelectrophoresis:
positive  light-chains
Biopsy:  positive  TTR  Biopsy:  positive
TTR
Biopsy:  positive  TTR  Myocardial  biopsy:
positive  TTR;  negative
light-chains
Genetic
Mutation  ATTR  mutation  ATTR  mutation  ATTR  mutation  No  ATTR  mutation
AL: light-chain amyloidosis; ATTR: hereditary transthyretin-related amyloidosis; BNP: B-type natriuretic peptide; cMRI: cardiac magnetic resonance imaging; CTS: carpal tunnel syndrome;
DPD: 3-3-diphosphono-1-2-propanodicarboxylic acid; ECG: electrocardiogram; LGE: late gadolinium enhancement; LV: left ventricular; LVEF: left ventricular ejection fraction; RVH: right
ventricular hypertrophy; SSA: systemic senile amyloidosis; TTE; transthoracic echocardiography; TTR: transthyretin.
a Increase in LV strain means decrease in left ventricular contractility.
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myocardial  disease  in  the  senile  group,  suggests  that  heart
failure  in  cardiac  AL  may  have  a  toxic  component,  related
to  the  direct  toxicity  of  the  circulating  monoclonal  LC  [58]
on  the  myocyte.  Another  study  [59],  focusing  on  survival
analysis  of  patients  with  amyloid  cardiomyopathy,  showed
that  the  hereditary  ATTR  aetiology  appeared  as  an  inde-
pendent  predictor  of  better  survival  compared  with  AL
patients.
Clinical implications
There  are  three  main  questions  that  the  clinician  should  be
aware  of:  how  to  detect  cardiac  amyloidosis;  when  to  think
about  it;  and  to  whom  to  refer  the  patient?
In  fact,  a  patient  with  dyspnoea,  unexplained  fatigue  and
LV  hypertrophy  on  TTE  contrasting  with  the  microvoltage  of
QRS  amplitude  should  alert  the  clinician  to  an  inﬁltrative
process  rather  than  a  classical  sarcomeric  hypertrophic  or
hypertensive  cardiomyopathy;  in  this  case  it  is  important  to
refer  the  patient  to  a  specialist  in  internal  medicine  and/or
a  haematologist  to  perform  more  speciﬁc  biological  and/or
genetic  testing,  as  described  above.
Conclusion
Cardiac  involvement  in  amyloidosis  remains  difﬁcult  to
diagnose  and  treat.  Extracardiac  signs,  in  addition  to  unex-
plained  LV  thickening  on  echocardiography  in  the  absence  of
increased  voltage  on  ECG,  favour  amyloid  cardiomyopathy.
Conﬁrmation  of  amyloid  type  is  now  possible  in  most  cases,
using  different  modern  methods.  The  cMRI  pattern  of  LGE
appears  to  be  very  characteristic. 99mTc-DPD  scintigraphy  is
an  interesting  technique  for  revealing  the  cardiac  deposits
of  ATTR  and  SSA.
Unlike  other  causes  of  heart  failure,  supportive  treat-
ment  is  usually  very  limited  and  can  be  dangerous.  Despite
important  developments  in  chemotherapy  for  AL,  the  prog-
nosis  of  patients  with  advanced  cardiac  involvement  remains
poor.  SSA  is  probably  often  underdiagnosed  but  has  a  better
prognosis  than  AL  and  ATTR.
Finally,  a  variety  of  novel  speciﬁc  therapies  are  on
the  horizon,  which  can  inhibit  new  amyloid  formation  and
enhance  clearance  of  existing  deposits.
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